This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates

Stock quotes in this article: AVNR

ALISO VIEJO, Calif., Sept. 20, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced several business updates. The highlights are being provided in connection with the company's presentation today at the UBS Global Life Sciences Conference in New York City.

Highlights include:

  • Exceeding 10,000 total NUEDEXTA® prescriptions for the month of August.
    • NUEDEXTA prescriptions of 10,710 in August represent 9% growth over the month of July.
    • August monthly prescriptions annualize to a gross NUEDEXTA sales run-rate of over $65 million.
    • Achieved record weekly prescriptions of 2,552 for the week-ending September 7, 2012
  • Presentation of interim PRISM Registry data at the 16 th Congress of the European Federation of Neurological Societies (EFNS) in Stockholm Sweden. Dr. Jonathan Fellus' presentation entitled The PRISM Registry: A Novel Research Tool to Estimate the Prevalence of Pseudobulbar Affect highlighted data showing that of the 4,349 enrolled patients, approximately 37% of all participants had PBA symptoms as measured by a CNS-LS score ≥13.
  • Strong interest and robust recruitment in the AVP-923 phase II clinical study of agitation in Alzheimer's disease demonstrated across eight sites currently recruiting patients.*
  • Recent submission of responses to the European Medicines Agency (EMA) for the NUEDEXTA Marketing Authorization Application (MAA). The submitted responses address the "Day-120" questions posed by the EMA in March 2012. Based on the review timelines, Avanir expects to receive an opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the NUEDEXTA MAA by the first calendar quarter of 2013.

A live webcast and 30-day archive of the presentation given at the UBS Global Life Sciences Conference will be available at http://ir.avanir.com.

About Pseudobulbar Affect

People with pseudobulbar affect (PBA) have sudden outbursts of involuntary crying or laughing, even though there may not be anything particularly sad or funny to trigger those emotions. Many people who suffer from PBA describe their episodes as uncontrollable, exaggerated, or different from their true feelings. PBA may occur when certain neurologic diseases or injury damage the areas of the brain that control normal expression of emotion. This damage can disrupt brain signaling, causing a "short circuit" and triggering episodes of involuntary crying or laughing. PBA can occur in people diagnosed with a variety of otherwise unrelated neurologic conditions such as Lou Gehrig's disease (ALS), multiple sclerosis (MS), Parkinson's disease, stroke, traumatic brain injury (TBI), and Alzheimer's disease. For more information about PBA, please visit www.PBAinfo.org.

About NUEDEXTA

NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,798.28 -6.43 -0.04%
S&P 500 1,946.78 +0.62 0.03%
NASDAQ 4,426.6640 +4.5790 0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs